Clementia reports Phase II data for rare bone disease candidate

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) reported data from a Phase II trial of palovarotene to treat fibrodysplasia ossificans progressiva (FOP). FOP is a rare, genetic bone disease characterized by heterotopic ossification (HO), or bone formation outside of the normal skeleton in muscles, tendons or soft tissue.

Part B of the open-label, international trial

Read the full 515 word article

User Sign In